You are here

ASCO 2022

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

BioSpace

Thu, 07/7/22 - 10:29 am

The mystery of Jemperli’s rectal cancer breakthrough

EP Vantage

Mon, 06/20/22 - 10:28 am

Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

BioSpace

Wed, 06/8/22 - 10:42 am

clinical trials

CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

BioSpace

Wed, 06/8/22 - 10:37 am

Jazz Pharmaceuticals

Merck Predicts Over 80 Potential Oncology Approvals Through 2028

BioSpace

Wed, 06/8/22 - 10:32 am

Roche keeps the faith in new cancer immunotherapy despite trial setbacks

BioPharma Dive

Tue, 06/7/22 - 10:30 am

clinical trials

ASCO 2022 – the spirit of Rova-T struggles to live on

EP Vantage

Tue, 06/7/22 - 10:19 am

Harpoon Therapeutics

Boehringer Ingelheim

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

Fierce Biotech

Tue, 06/7/22 - 10:16 am

NRG1 fusion-positive cancer

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

Pharmaforum

Mon, 06/6/22 - 11:52 pm

antibody-drug conjugate

Bristol Myers Squibb

Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

BioSpace

Mon, 06/6/22 - 11:48 pm

HER2-negative breast cancer

ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says

Fierce Biotech

Mon, 06/6/22 - 10:33 am

Mirati Therapeutics

#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

Endpoints

Mon, 06/6/22 - 10:31 am

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

BioSpace

Mon, 06/6/22 - 10:03 am

clinical trials

ASCO 2022 – Carvykti casts a long shadow

EP Vantage

Mon, 06/6/22 - 10:01 am

Multiple Myeloma

ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance

Fierce Pharma

Mon, 06/6/22 - 09:59 am

Bristol Myers Squibb

ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance

Fierce Pharma

Mon, 06/6/22 - 09:57 am

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Pharmaforum

Mon, 06/6/22 - 09:52 am

bispecific antibodies

relapsed or refractory multiple myeloma

ASCO22: Enhertu aces key HER2-low test in breast cancer

Pharmaforum

Mon, 06/6/22 - 09:43 am

HER2-low breast cancer

ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer

Fierce Biotech

Sun, 06/5/22 - 11:45 pm

cancer vaccines

pancreatic cancer

ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt

Fierce Pharma

Sun, 06/5/22 - 11:42 pm

Gilead Sciences

Pages